Health Care • Biotechnology: Pharmaceutical Preparations
$4.21 ▼ -0.07
(-1.64%)
MKT CAP: $656.0M • VOL: 2.53M
52W L $4 52W H $5
ABUS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $14.1M | $6.2M | $18.1M |
| YoY Revenue Growth % | +128.2% | -66.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$38.2M | -$76.3M | -$78.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$33.5M | -$69.9M | -$72.8M |
| EBITDA (Normalized) | -$38.2M | -$76.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$39.6M | -$64.8M | -$85.9M |
| Capital Expenditures (CapEx) | $0 | $182.0K | — |
| Free Cash Flow (FCF) | -$39.6M | -$65.0M | -$85.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $18.0M | $36.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $76.6M | $97.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABUS.